Ravulizumab
Orphan Drug Cold Chain RequiredFDA Approved
Description
Ravulizumab is a monoclonal antibody that inhibits the complement C5 protein, preventing its cleavage into C5a and C5b. It is used to treat certain complement-mediated disorders.
Indications & Therapeutic Use
Acute Lung Injury
Linked Diseases:
acute lung injury
D055371
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Ravulizumab
| Generic Name | Ravulizumab |
| Brands | 1 brand available |
| Active Ingredient | Ravulizumab |
| Drug Class | Acute Lung Injury |
| Manufacturer | Alexion Pharmaceuticals |
| Dosage Forms | IV infusion |
| Medical Code | V03AX09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03056040 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes